These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 11366716

  • 1. Action alert: drug-patent bill could cost patients $3 billion+; hearing July 1.
    AIDS Treat News; 1999 Jun 18; (No 321):8. PubMed ID: 11366716
    [Abstract] [Full Text] [Related]

  • 2. AIDS drugs. Brazil, Thailand override big pharma patents.
    Cohen J.
    Science; 2007 May 11; 316(5826):816. PubMed ID: 17495145
    [No Abstract] [Full Text] [Related]

  • 3. Generic drugs.
    AIDS Policy Law; 1999 Nov 26; 14(21):16. PubMed ID: 11367114
    [Abstract] [Full Text] [Related]

  • 4. The Claritin case: how one firm played the patent game.
    Novak V.
    Time; 1999 Nov 22; 154(21):42. PubMed ID: 10622840
    [No Abstract] [Full Text] [Related]

  • 5. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
    Berger JM.
    Conn J Int Law; 2002 Nov 22; 17(2):157-248. PubMed ID: 12688292
    [No Abstract] [Full Text] [Related]

  • 6. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug 29; 18(16):6. PubMed ID: 14626916
    [No Abstract] [Full Text] [Related]

  • 7. [The patent legislation in India fails the HIV/AIDS work].
    Holen Ø.
    Tidsskr Nor Laegeforen; 2005 Oct 06; 125(19):2666-7. PubMed ID: 16215618
    [No Abstract] [Full Text] [Related]

  • 8. Global patent police block cost-reduction efforts.
    Kasper T.
    GMHC Treat Issues; 1999 Mar 06; 13(3):1-2. PubMed ID: 11366201
    [Abstract] [Full Text] [Related]

  • 9. A generic problem.
    Hanauer SB.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec 06; 3(12):649. PubMed ID: 17130869
    [No Abstract] [Full Text] [Related]

  • 10. Are patent expirations the answer to improving patient adherence?
    Klepser DG.
    Am J Manag Care; 2008 Dec 06; 14(12):787-8. PubMed ID: 19067495
    [No Abstract] [Full Text] [Related]

  • 11. Patent. Battle lines are drawn over generic AIDS drug.
    AIDS Policy Law; 2005 Aug 26; 20(16):6. PubMed ID: 16161208
    [No Abstract] [Full Text] [Related]

  • 12. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA.
    Food Drug Law J; 2000 Aug 26; 55(3):321-41. PubMed ID: 11824464
    [No Abstract] [Full Text] [Related]

  • 13. "No turning back" on cheap AIDS drugs for poor nations, UN vows.
    Silversides A.
    CMAJ; 2003 Nov 11; 169(10):1067. PubMed ID: 14609992
    [No Abstract] [Full Text] [Related]

  • 14. TRIPS: generic irony.
    Howarth GR.
    Br J Gen Pract; 2002 Jan 11; 52(474):57. PubMed ID: 11791819
    [No Abstract] [Full Text] [Related]

  • 15. Generics battle brand names over mortality of drug patents.
    Betz R.
    J Healthc Resour Manag; 1995 Jul 11; 13(7):35-7. PubMed ID: 10144008
    [No Abstract] [Full Text] [Related]

  • 16. Drug costs threaten patent protection.
    Cimons M.
    Nat Med; 2003 Jan 11; 9(1):9. PubMed ID: 12514706
    [No Abstract] [Full Text] [Related]

  • 17. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B, Miller LG, Kuo MN, Bradley J, Scheld WM, Edwards JE.
    Infection; 2007 Jun 11; 35(3):167-74. PubMed ID: 17565458
    [Abstract] [Full Text] [Related]

  • 18. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
    Cohen J.
    Science; 2006 Jul 28; 313(5786):484-7. PubMed ID: 16873654
    [No Abstract] [Full Text] [Related]

  • 19. . . . and Brazilian AIDS programme threatened by US trade action.
    Int J Epidemiol; 2001 Apr 28; 30(2):413. PubMed ID: 11369751
    [No Abstract] [Full Text] [Related]

  • 20. US policy may encourage counterfeit drugs.
    Bouchie A.
    Nat Biotechnol; 2003 Feb 28; 21(2):121. PubMed ID: 12560826
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.